- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05083572
Effect of Probiotic on Gut Microbiome and Bacterial Translocation in Healthy Asian Volunteers
Effect of Probiotic (Vivomixx/ DeSimone Formulation) on Gut Microbiome and Bacterial Translocation in Healthy Asian Volunteers - An Exploratory Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This will be a randomized controlled, partially-blinded study with four study arms to (i) examine the effect of Vivomixx on the gut microbiome with and without colonic lavage, (ii) with and without antibiotic treatment, (iii) compare the gut microbiome after natural recovery and with Vivomixx treatment following colonic lavage, and (iv) evaluate the efficacy of Vivomixx in reducing bacterial translocation and oxidative stress.
Screening Visit Procedures (within 28 days of first dosing):
- Informed consent;
- Demography, including date of birth, sex, and race/ethnicity;
- Body weight and height measurement;
- Determination of eligibility based on inclusion/exclusion criteria;
- Adverse event/concomitant medication check;
- Complete medical/drug history;
- Alcohol/Smoking history;
- Blood pressure, heart rate and temperature, taken after resting at a sitting position for at least 5 minutes;
- Complete physical examination;
- Laboratory safety tests (liver panel, renal panel and complete blood count) (10 ml blood);
- Urine dipstick pregnancy test (for female subjects only).
Day -14 Procedures (for Group D only):
On reporting to CTRU on Day -14, participants will be reminded of study restrictions and undergo the following assessments:
- Interim medical/drug history;
- Adverse event/concomitant medication check;
- Blood pressure, heart rate and temperature, taken after resting at a sitting position for at least 5 minutes;
- Complete physical examination;
- Provision of baseline stool sample ~3g (before dosing with rifaximin) (for microbiome and SCFA);
- Provision of baseline blood sample ~12ml for flow cytometry and SCFA analysis (before dosing with rifaximin);
- Rifaximin on-site dosing;
- Rifaximin dispensing for home consumption (1 tablet 200mg daily till Day -7).
Day -7 Procedures (for Group D only):
On reporting to CTRU on Day -7, participants will be reminded of study restrictions and undergo the following assessments:
- Interim medical/drug history;
- Adverse event/concomitant medication check;
- Blood pressure, heart rate and temperature, taken after resting at a sitting position for at least 5 minutes;
- Brief physical examination;
- Provision of stool sample ~3g (for microbiome and SCFA);
- Provision of blood sample ~12ml for flow cytometry and SCFA analysis;
- Rifaximin home dosing (1 tablet 200mg in morning);
- Return of rifaximin for accountability check;
- Rifaximin dispensing for home consumption (1 tablet 200mg daily till Day 1).
Day -1 Procedures (for Groups A & B only):
On reporting to CTRU on Day -1, participants will be reminded of study restrictions and undergo the following assessments:
- Interim medical/drug history;
- Adverse event/concomitant medication check;
- Blood pressure, heart rate and temperature, taken after resting at a sitting position for at least 5 minutes;
- Complete physical examination;
- Provision of baseline stool sample ~3g (before dosing with PEG) (for microbiome and SCFA);
- Provision of baseline blood sample ~12ml for flow cytometry and SCFA analysis (before dosing with PEG);
- PEG dispensing for colonic lavage (home consumption- 2L at 6pm);
- Telephone call at night for bowel movement and AE check.
Day 1 Procedures:
• Home consumption of 2L PEG at 6am for colonic lavage.
On reporting to CTRU on Day 1, participants will be reminded of study restrictions and undergo the following assessments:
- Interim medical/drug history (for Group C only);
- Adverse event/concomitant medication check;
- Blood pressure, heart rate and temperature, taken after resting at a sitting position for at least 5 minutes (for Group C only);
- Complete physical examination;
- Verbal stool symptom assessment (for Group D only);
- Laboratory safety tests (liver panel, renal panel and complete blood count) (10 ml blood) (for Group D only);
- Biomarker test (5 ml blood before dosing) (for Group C only);
- Endotoxaemia test (5 ml blood 2hrs post-meal) (for Group C only);
- Provision of stool sample ~3g (before dosing with Vivomixx or Placebo) (for microbiome and SCFA);
- Provision of blood sample ~12ml for flow cytometry and SCFA analysis (before dosing with Vivomixx or Placebo);
- Vivomixx (Groups A, C & D) or Placebo (Group B) on-site dosing;
- Return of PEG (Groups A & B) or rifaximin (Group D) for accountability check;
- Vivomixx or Placebo dispensing for home consumption.
Day 2-28 Procedures:
- Self-administration of 2 capsules of Vivomixx (Groups A, C & D) or Placebo (Group B) twice daily (morning and evening) till Day 28;
- Consumption of the study products will be monitored real-time via electronic means on mobile devices (video call). All morning dosing should be between 8-10am, and all evening dosing should happen between 6-8pm;
- Verbal stool symptom assessment on Day 14.
Day 29 Procedures (+ 2 days):
On reporting to CTRU on Day 29, participants will be reminded of study restrictions and undergo the following assessments:
- Adverse event/concomitant medication check;
- Blood pressure, heart rate and temperature, taken after resting at a sitting position for at least 5 minutes;
- Verbal stool symptom assessment;
- Complete physical examination;
- Laboratory safety tests (liver panel, renal panel and complete blood count) (10 ml blood);
- Biomarker and endotoxaemia tests (10 ml blood) (for Group C only);
- Provision of stool sample ~3g (for microbiome and SCFA);
- Provision of blood sample ~12ml for flow cytometry and SCFA analysis;
- Vivomixx (Groups A, C & D) or Placebo (Group B) home dosing (2 capsules in morning and evening);
- Return of Vivomixx (Groups A, C & D) or Placebo (Group B) for accountability check.
Day 56 Procedures (± 3 days) (Final Visit):
- Adverse event/concomitant medication check;
- Brief physical examination;
- Verbal stool symptom assessment;
- Provision of stool sample ~3g (for microbiome and SCFA);
- Provision of blood sample ~12ml for flow cytometry and SCFA analysis.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Seok Hwee Koo, PhD
- Phone Number: +6568504929
- Email: seok_hwee_koo@cgh.com.sg
Study Locations
-
-
-
Singapore, Singapore, 529889
- Recruiting
- Changi General Hospital
-
Sub-Investigator:
- Seok Hwee Koo
-
Sub-Investigator:
- Chin Kimg Tan
-
Contact:
- Siok Luan Ong
-
Sub-Investigator:
- Edmund Jon Deoon Lee
-
Sub-Investigator:
- Eugene Yu Jun Wong
-
Sub-Investigator:
- May Gloriba Manejero Fria
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provision of signed written informed consent,
- Aged between 21-65 years of age,
- Chinese, Malay or Indian ancestry through three generations,
- Body Weight ≥ 50kg, Body Mass Index (BMI) of 18.5 to 29.9 kg/m2, inclusive,
- Clinical laboratory assessment results within normal limits, unless the deviation is considered not clinically significant by the investigator,
- Regular stool every 1-2 days,
- Satisfactory medical assessment as assessed by physical examination, medical history, and normal laboratory values or minor variations that are not clinically significant,
- Ability to communicate with the investigator and to understand and comply with all requirements of study participation.
- Both male and female participants (with child-bearing potential) and their partners have to practise contraception throughout the duration of the study.
Exclusion Criteria:
- Any acute illness within 14 days of first dosing, unless otherwise approved by the PI,
- History or evidence of clinically significant hepatic, renal, cardiovascular, respiratory, gastrointestinal, immunosuppressive or metabolic disorders, any cancer types,
- Declare themselves positive for HIV or viral hepatitis (Hepatitis A, B, C),
- Treatment within the previous 3 months with antibiotics (subjects are to inform study staff should they be prescribed antibiotics during the course of the study)
- Treatment with any prescription or over-the-counter medications, complementary health products, or herbal supplements within 28 days of first dosing,
- Consumption of probiotics or lactobacillus-containing products e.g. Yakult, Vitagen or Yogurt within 4 weeks of first dosing unless approved by the PI,
- Abnormal biochemistry indicators, unless certified as not clinically significant,
- Poor peripheral venous access,
- Irregular bowel habits or complains of constipation problem,
- Pregnancy or lactation,
- Known allergic reactions to rifaximin, PEG or Vivomixx,
- History of drug/alcohol abuse,
- Involvement in the planning or conduct of this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group A (Lavage and Vivomixx)
Colonic lavage, followed by Vivomixx treatment
|
The subjects will orally consume a split dose of bowel preparation (PEG); 2 litres in the evening (Day -1) and another 2 litres the following morning (Day 1).
Other Names:
The subjects will self-administer orally two capsules of Vivomixx with room temperature water (as heat may inactivate the live bacteria, rendering it less effective) twice daily for 28 days.
Other Names:
|
Experimental: Group B (Lavage and Placebo)
Colonic lavage, followed by Placebo treatment
|
The subjects will orally consume a split dose of bowel preparation (PEG); 2 litres in the evening (Day -1) and another 2 litres the following morning (Day 1).
Other Names:
|
Experimental: Group C (Vivomixx)
No colonic lavage, only Vivomixx treatment
|
The subjects will self-administer orally two capsules of Vivomixx with room temperature water (as heat may inactivate the live bacteria, rendering it less effective) twice daily for 28 days.
Other Names:
|
Experimental: Group D (Rifaximin and Vivomixx)
Rifaximin, followed by Vivomixx treatment
|
The subjects will self-administer orally two capsules of Vivomixx with room temperature water (as heat may inactivate the live bacteria, rendering it less effective) twice daily for 28 days.
Other Names:
The subjects will undergo pre-treatment to "cleanse" the gut by consuming orally one tablet of antibiotic rifaximin (200mg) daily for 14 days prior to the initiation of Vivomixx course.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Microbiome profile using 16S rRNA sequencing
Time Frame: 2 to 2.5 months
|
Fresh stool samples will be collected for microbial DNA extraction at Days -14 and -7 (Group D), Day -1 (Groups A & B), Days 1, 29 and 56 (All groups).
Microbial DNA will be extracted from the stool samples and used for 16S rRNA sequencing.
Bacterial species present in Vivomixx will be specifically examined.
|
2 to 2.5 months
|
Inflammatory cytokines using ELISA tests
Time Frame: 2 to 2.5 months
|
Inflammatory cytokines indicative of oxidative damage will be assayed using commercially available Elisa kits on serum samples obtained at Baseline and Day 29 (For Group C only).
|
2 to 2.5 months
|
Bacterial translocation using endotoxin assay
Time Frame: 2 to 2.5 months
|
Blood will be collected 2 hours post meal at baseline and Day 29 for endotoxin LAL assay using commercial kit (For Group C only).
|
2 to 2.5 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Peripheral blood lymphocyte phenotyping using flow cytometry
Time Frame: 2 to 2.5 months
|
Blood will be collected at specified timepoints for peripheral blood lymphocyte phenotyping by flow cytometry
|
2 to 2.5 months
|
Short chain fatty acids using mass spectrometry
Time Frame: 2 to 2.5 months
|
Stool and blood will be collected at specified timepoints for short chain fatty acid analysis by gas chromatography-mass spectrometry
|
2 to 2.5 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Tiing Leong Ang, Changi General Hospital
Publications and helpful links
General Publications
- Jalanka J, Salonen A, Salojarvi J, Ritari J, Immonen O, Marciani L, Gowland P, Hoad C, Garsed K, Lam C, Palva A, Spiller RC, de Vos WM. Effects of bowel cleansing on the intestinal microbiota. Gut. 2015 Oct;64(10):1562-8. doi: 10.1136/gutjnl-2014-307240. Epub 2014 Dec 19.
- Valentini L, Pinto A, Bourdel-Marchasson I, Ostan R, Brigidi P, Turroni S, Hrelia S, Hrelia P, Bereswill S, Fischer A, Leoncini E, Malaguti M, Blanc-Bisson C, Durrieu J, Spazzafumo L, Buccolini F, Pryen F, Donini LM, Franceschi C, Lochs H. Impact of personalized diet and probiotic supplementation on inflammation, nutritional parameters and intestinal microbiota - The "RISTOMED project": Randomized controlled trial in healthy older people. Clin Nutr. 2015 Aug;34(4):593-602. doi: 10.1016/j.clnu.2014.09.023. Epub 2014 Oct 8.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Vivomixx
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dysbiosis
-
Experimental and Clinical Research CenterEnrolling by invitationGut Microbiota Dysbiosis and NutritionGermany
-
Jagiellonian UniversityCompletedMicrobiota, Cesarean Section, Probiotics, Dysbiosis
-
Copenhagen University Hospital, HvidovreCompletedTransplantation | Vaginal Dysbiosis | Vaginal MicrobiomeDenmark
-
Mucosa Innovations, S.L.Universidad de GranadaActive, not recruiting
-
International Centre for Diarrhoeal Disease Research...Bill and Melinda Gates FoundationRecruitingEnvironmental Enteric Dysfunction | Gut Microbiota DysbiosisBangladesh
-
National Taiwan University HospitalRecruitingGut Dysbiosis for TMAO Production From L-carnitine ConsumptionTaiwan
-
University of PalermoCompletedDysbiosis Symptoms Linked to PathologyItaly
-
Persephone BiosciencesActive, not recruiting
-
Sophie Bucher Della TorreUniversity Hospital, GenevaActive, not recruiting
-
University of California, DavisCompleted
Clinical Trials on Colonic lavage with polyethylene glycol
-
University of OklahomaCompletedDiabetes MellitusUnited States
-
Ikazia Hospital, RotterdamCompletedAnastomotic Dehiscence in Colorectal SurgeryNetherlands
-
Azienda Policlinico Umberto IAzienda Ospedaliera Ospedale Infantile Regina Margherita Sant'AnnaCompletedConstipation | Faecal Impaction
-
Orion Corporation, Orion PharmaCompleted
-
Changhai HospitalUnknownAdenoma Detection Rate | Bowel Preparation ScaleChina
-
Cook County HealthCompletedBowel Preparation for ColonoscopyUnited States
-
Cleveland Clinic FloridaCompletedColon CancerUnited States
-
Oregon Health and Science UniversityUnknownColonoscopyUnited States
-
Air Force Military Medical University, ChinaCompletedColonoscopy | Bowel Preparation | Predictive ModelChina
-
Shandong UniversityCompleted